These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 26786928)

  • 41. [Metastatic melanoma: some hope from ipilimumab and vemurafenib].
    Piérard-Franchimont C; Piérard GE
    Rev Med Liege; 2012 Feb; 67(2):64-8. PubMed ID: 22482234
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of brain metastases in patients with melanoma.
    Fisher R; Larkin J
    Lancet Oncol; 2012 May; 13(5):434-5. PubMed ID: 22456430
    [No Abstract]   [Full Text] [Related]  

  • 43. Sigmoid diverticulosis--a risk factor for perforation of the sigmoid colon due to ipilimumab-associated enterocolitis?
    Hrgovic I; Winkelmann R; Vogl TJ; von Wagner M; El Youzouri H; Kaufmann R; Meissner M
    J Dtsch Dermatol Ges; 2015 Jun; 13(6):575-7. PubMed ID: 26018375
    [No Abstract]   [Full Text] [Related]  

  • 44. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
    Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
    Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ipilimumab-induced colitis in patients with metastatic melanoma.
    De Felice KM; Gupta A; Rakshit S; Khanna S; Kottschade LA; Finnes HD; Papadakis KA; Loftus EV; Raffals LE; Markovic SN
    Melanoma Res; 2015 Aug; 25(4):321-7. PubMed ID: 25933207
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An Autoimmune Haemolytic Anaemia Secondary to Ipilimumab Treatment.
    Ramos B; Gastal G; Rovere RK
    Klin Onkol; 2017; 30(2):128-130. PubMed ID: 28397508
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ipilimumab in melanoma patients with brain metastasis: a retro-spective multicentre evaluation of thirty-eight patients.
    Konstantinou MP; Dutriaux C; Gaudy-Marqueste C; Mortier L; Bedane C; Girard C; Thellier S; Jouary T; Grob JJ; Richard MA; Templier C; Sakji L; Guillot B; Paul C; Meyer N
    Acta Derm Venereol; 2014 Jan; 94(1):45-9. PubMed ID: 23824275
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
    Hoos A; Ibrahim R; Korman A; Abdallah K; Berman D; Shahabi V; Chin K; Canetta R; Humphrey R
    Semin Oncol; 2010 Oct; 37(5):533-46. PubMed ID: 21074069
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multiple colon perforation as a fatal complication during treatment of metastatic melanoma with ipilimumab - case report.
    Dilling P; Walczak J; Pikiel P; Kruszewski WJ
    Pol Przegl Chir; 2014 Feb; 86(2):94-6. PubMed ID: 24670341
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Subclinical aortitis after starting nivolumab in a patient with metastatic melanoma. A case of drug-associated aortitis?
    Loricera J; Hernández JL; García-Castaño A; Martínez-Rodríguez I; González-Gay MÁ; Blanco R
    Clin Exp Rheumatol; 2018; 36 Suppl 111(2):171. PubMed ID: 29799390
    [No Abstract]   [Full Text] [Related]  

  • 51. Ipilimumab in patients with melanoma and brain metastases.
    Nieder C
    Lancet Oncol; 2012 Jul; 13(7):e277; author reply e277-8. PubMed ID: 22748259
    [No Abstract]   [Full Text] [Related]  

  • 52. Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma.
    Kähler KC; Hassel JC; Heinzerling L; Loquai C; Mössner R; Ugurel S; Zimmer L; Gutzmer R;
    J Dtsch Dermatol Ges; 2016 Jul; 14(7):662-81. PubMed ID: 27373241
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Left Ventricular Dysfunction After Treatment With Ipilimumab for Metastatic Melanoma.
    Roth ME; Muluneh B; Jensen BC; Madamanchi C; Lee CB
    Am J Ther; 2016; 23(6):e1925-e1928. PubMed ID: 26885708
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ipilimumab for advanced metastatic melanoma.
    Starz H
    Expert Opin Biol Ther; 2012 Aug; 12(8):981-2. PubMed ID: 22690756
    [No Abstract]   [Full Text] [Related]  

  • 55. Antiphospholipid syndrome associated with combined immune checkpoint inhibitor therapy.
    Gupta A; Shah U; Khine H; Vandergriff T; Froehlich T
    Melanoma Res; 2017 Apr; 27(2):171-173. PubMed ID: 28099367
    [No Abstract]   [Full Text] [Related]  

  • 56. Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis.
    Jain A; Lipson EJ; Sharfman WH; Brant SR; Lazarev MG
    World J Gastroenterol; 2017 Mar; 23(11):2023-2028. PubMed ID: 28373768
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial.
    Weber JS; Amin A; Minor D; Siegel J; Berman D; O'Day SJ
    Melanoma Res; 2011 Dec; 21(6):530-4. PubMed ID: 22051508
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Renal Allograft Failure After Ipilimumab Therapy for Metastatic Melanoma: A Case Report and Review of the Literature.
    Jose A; Yiannoullou P; Bhutani S; Denley H; Morton M; Picton M; Summers A; van Dellen D; Augustine T
    Transplant Proc; 2016 Nov; 48(9):3137-3141. PubMed ID: 27932166
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Subacute CNS Demyelination after Treatment with Nivolumab for Melanoma.
    Maurice C; Schneider R; Kiehl TR; Bavi P; Roehrl MH; Mason WP; Hogg D
    Cancer Immunol Res; 2015 Dec; 3(12):1299-302. PubMed ID: 26419960
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Azathioprine combination therapy for steroid-refractory hepatic immune system-related adverse events.
    Iwamoto K; Ishitsuka Y; Tanaka R; Sekine I; Fujimoto M
    Eur J Dermatol; 2017 Jun; 27(3):301-303. PubMed ID: 28468733
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.